Suppr超能文献

G 蛋白偶联受体(GPCRs)的偏性配体:结构-功能选择性关系(SFSRs)和治疗潜力。

Biased Ligands of G Protein-Coupled Receptors (GPCRs): Structure-Functional Selectivity Relationships (SFSRs) and Therapeutic Potential.

机构信息

iHuman Institute , ShanghaiTech University , 393 Middle Huaxia Road , Pudong District, Shanghai 201210 , China.

Department of Cell Biology, Neurobiology and Anatomy , Medical College of Wisconsin , 8701 W. Watertown Plank Road , Milwaukee , Wisconsin 53226 , United States.

出版信息

J Med Chem. 2018 Nov 21;61(22):9841-9878. doi: 10.1021/acs.jmedchem.8b00435. Epub 2018 Jul 10.

Abstract

G protein-coupled receptors (GPCRs) signal through both G-protein-dependent and G-protein-independent pathways, and β-arrestin recruitment is the most recognized one of the latter. Biased ligands selective for either pathway are expected to regulate biological functions of GPCRs in a more precise way, therefore providing new drug molecules with superior efficacy and/or reduced side effects. During the past decade, biased ligands have been discovered and developed for many GPCRs, such as the μ opioid receptor, the angiotensin II receptor type 1, the dopamine D receptor, and many others. In this Perspective, recent advances in this field are reviewed by discussing the structure-functional selectivity relationships (SFSRs) of GPCR biased ligands and the therapeutic potential of these molecules. Further understanding of the biological functions associated with each signaling pathway and structural basis for biased signaling will facilitate future drug design in this field.

摘要

G 蛋白偶联受体(GPCRs)通过 G 蛋白依赖和非依赖途径信号转导,β-arrestin 的募集是后者最被认可的途径之一。偏向配体对任一路径的选择性预计将以更精确的方式调节 GPCR 的生物学功能,因此提供具有更高疗效和/或更低副作用的新型药物分子。在过去的十年中,已经发现并开发了许多 GPCR 的偏向配体,例如μ阿片受体、血管紧张素 II 受体 1、多巴胺 D 受体等。在这篇观点文章中,通过讨论 GPCR 偏向配体的结构-功能选择性关系(SFSR)和这些分子的治疗潜力,综述了该领域的最新进展。进一步了解与每条信号通路相关的生物学功能和偏向信号的结构基础,将有助于该领域的药物设计。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验